SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Global burden of disease. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_ full.pdf. Accessed August 8, 2011.
  • 2
    Centers for Disease Control and Prevention. Chronic liver disease or cirrhosis. http://www.cdc.gov/nchs/fastats/liverdis.htm. Accessed August 8, 2011.
  • 3
    American Liver Foundation. Liver life challenge. http://www.liverfoun dation.org/. Accessed August 8, 2011.
  • 4
    Centers for Disease Control and Prevention. National hospital discharge survey: 2005 annual summary with detailed diagnosis and procedure data. http://www.cdc.gov/nchs/data/series/sr_13/sr13_165.pdf. Accessed August 8, 2011.
  • 5
    Arabi Y, Ahmed QA, Haddad S, Aljumah A, Al-Shimemeri A. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol 2004; 16: 333-339.
  • 6
    Filloux B, Chagneau-Derrode C, Ragot S, Voultoury J, Beauchant M, Silvain C, et al. Short-term and long-term vital outcomes of cirrhotic patients admitted to an intensive care unit. Eur J Gastroenterol Hepatol 2010; 22: 1474-1480.
  • 7
    Olson JC, Kamath PS. Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr Opin Crit Care 2011; 17: 165-169.
  • 8
    Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124: 1016-1020.
  • 9
    Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol 2007; 41: 403-411.
  • 10
    Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-48.
  • 11
    Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th Meeting of the International Ascites Club. Gut 2005; 54: 718-725.
  • 12
    Navasa M, Fernandez J, Rodes J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol 1999; 31: 616-625.
  • 13
    Karvellas CJ, Pink F, McPhail M, Austin M, Auzinger G, Bernal W, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med 2010; 38: 121-126.
  • 14
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409.
  • 15
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
  • 16
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
  • 17
    Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
  • 18
    Canabal JM, Kramer DJ. Management of sepsis in patients with liver failure. Curr Opin Crit Care 2008; 14: 189-197.
  • 19
    Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. HEPATOLOGY 2009; 50: 2022-2033.
  • 20
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
  • 21
    Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
  • 22
    Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.
  • 23
    Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-1785.
  • 24
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
  • 25
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464-470.
  • 26
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
  • 27
    Gilbert DN, Moellering RC Jr, Eliopoulos G. Clinical approach to initial choice of antimicrobial therapy. In: The Sanford Guide to Antimicrobial Therapy. Hyde Park, VT: Antimicrobial Therapy; 2004: 2-45.
  • 28
    Haukoos JS, Newgard CD. Advanced statistics: missing data in clinical research—part 1: an introduction and conceptual framework. Acad Emerg Med 2007; 14: 662-668.
  • 29
    Ulldemolins M, Nuvials X, Palomar M, Masclans JR, Rello J. Appropriateness is critical. Crit Care Clin 2011; 27: 35-51.
  • 30
    Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jimenez R, Barroso S, et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006; 10: R111.
  • 31
    Funk DJ, Kumar A. Antimicrobial therapy for life-threatening infections: speed is life. Crit Care Clin 2011; 27: 53-76.
  • 32
    Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164: 637-644.
  • 33
    Miner JR, Heegaard W, Mapes A, Biros M. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21: 387-392.
  • 34
    McCormick PA, Greenslade L, Kibbler CC, Chin JK, Burroughs AK, McIntyre N. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. HEPATOLOGY 1997; 25: 833-836.
  • 35
    Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3: 269-282.
  • 36
    Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. HEPATOLOGY 2000; 32: 734-739.
  • 37
    Connors AF Jr. Pitfalls in estimating the effect of interventions in the critically ill using observational study designs. Crit Care Med 2001; 29: 1283-1284.
  • 38
    Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care—associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797.